Neuland Laboratories Limited (BOM:524558)

Market Cap	250.40B +59.5%
Revenue (ttm)	20.23B +37.0%
Net Income	3.64B +39.9%
EPS	283.71 +39.9%
Shares Out	12.83M
PE Ratio	68.79
Forward PE	59.72
Dividend	34.00 (0.17%)
Ex-Dividend Date	Jul 24, 2026

Volume	1,586
Open	19,848
Previous Close	19,519
Day's Range	19,366 - 19,848
52-Week Range	11,500 - 20,072
Beta	0.29
Analysts	Strong Buy
Price Target	20,972.00 (+7.46%)
Earnings Date	Aug 6, 2026

About Neuland Laboratories

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1984
• Employees: 1,794
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524558

Financial Performance

In fiscal year 2026, Neuland Laboratories's revenue was 20.23 billion, an increase of 36.98% compared to the previous year's 14.77 billion. Earnings were 3.64 billion, an increase of 39.94%.

Analyst Summary

According to 4 analysts, the average rating for 524558 stock is "Strong Buy." The 12-month stock price target is ₹20,972, which is an increase of 7.46% from the latest price.

Price Target

₹20,972

(7.46% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 12, 2026

Data Sources Report a data error